PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M

 PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M

PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M

Shots:

  • PerkinElmer to acquire IDS in all cash transactions for ~$155M. The transaction is expected to be completed in Q3’21
  • The acquisition will allow PerkinElmer to foster its overall Diagnostics business and specifically its immunodiagnostics segment
  • The acquisition will integrate PerkinElmer’s channel expertise and testing capabilities with IDS’ chemiluminescence products in endocrinology, autoimmunity, and infectious diseases to better serve customers across the globe

Click here to­ read full press release/ article | Ref: Businesswire | Image: Wikipedia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post